MA39272A - Formulations à libération prolongée de gabapentine - Google Patents

Formulations à libération prolongée de gabapentine

Info

Publication number
MA39272A
MA39272A MA039272A MA39272A MA39272A MA 39272 A MA39272 A MA 39272A MA 039272 A MA039272 A MA 039272A MA 39272 A MA39272 A MA 39272A MA 39272 A MA39272 A MA 39272A
Authority
MA
Morocco
Prior art keywords
gabapentine
extended
release formulations
gabapentin
effective amount
Prior art date
Application number
MA039272A
Other languages
English (en)
Inventor
Yelda Erdem
Hande Torun
Ali Türkyilmaz
Original Assignee
Arven Ilac Sanayi Ve Ticaret As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret As filed Critical Arven Ilac Sanayi Ve Ticaret As
Publication of MA39272A publication Critical patent/MA39272A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une formulation à libération prolongée comprenant une quantité thérapeutiquement efficace de gabapentine et d'un agent de retardant la libération de celui-ci.
MA039272A 2014-04-09 2015-04-08 Formulations à libération prolongée de gabapentine MA39272A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR201404106 2014-04-09

Publications (1)

Publication Number Publication Date
MA39272A true MA39272A (fr) 2015-10-14

Family

ID=52808100

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039272A MA39272A (fr) 2014-04-09 2015-04-08 Formulations à libération prolongée de gabapentine

Country Status (2)

Country Link
EP (1) EP2929878A1 (fr)
MA (1) MA39272A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110917164B (zh) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 一种苯磺酸米洛巴林缓释片及其制备方法
WO2024043809A1 (fr) * 2022-08-26 2024-02-29 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Composition pharmaceutique comprenant de la gabapentine et de la benfotiamine, et forme médicamenteuse sur la base de celle-ci

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
BR9910508B1 (pt) * 1998-05-15 2012-01-24 preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico.
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.

Also Published As

Publication number Publication date
EP2929878A1 (fr) 2015-10-14

Similar Documents

Publication Publication Date Title
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
MA53356A (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MD3209309T2 (ro) Compoziții care conțin tulpini bacteriene
MD3204025T2 (ro) Compoziții care conțin tulpini bacteriene
MD3206700T2 (ro) Compoziții conținând tulpini bacteriene
BR112017006137A2 (pt) formulação que contém biotensoativo
MA45450B1 (fr) Formulations d'anticorps anti-cd19
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
BR112017005231A2 (pt) formulações eutéticas de cloridrato de ciclobenzaprina
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MA50670A (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
MA39272A (fr) Formulations à libération prolongée de gabapentine
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA45451A (fr) Formulations tensioactives destinées à l'inhalation
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
EA201792685A1 (ru) Фармацевтическая композиция для лечения воспалительных изменений прямой кишки
TR201714964A2 (tr) Efervesan tablet formülasyonları.
IL277358A (en) Omniphilic nanovesicles based on modified polysaccharides for the delivery of active substances
TR201819312A2 (tr) Fesoterodi̇ni̇n çi̇ft katmanli tablet formülasyonu
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
FR3069778B1 (fr) Composition comprenant un extrait de myrte et un sel de fluor destinee a une application bucco-dentaire